Drug recall notice for Chantix (varenicline) tablets

A couple researching a prescription online

To assist you in the care of your patients, we would like to alert you to the recall of all lots of Chantix® 0.5 mg and 1 mg tablets on Sept. 16, 2021.1 We recommend you review your medical records and contact all patients for whom you have prescribed this medication to warn them of the recall. 

The drug manufacturer, Pfizer, has voluntarily expanded the recall on these products to the patient (consumer/user) level due to the presence of a nitrosamine, N-nitroso-varenicline, at or above the U.S. Food and Drug Administration (FDA) acceptable intake limit. This recall is being conducted with the knowledge of the FDA.

Medications included in this recall

Visit the FDA website for specific details about the recalled medication.

Recommendations

To reduce impact to your patients, please consider the listed alternative options below.* (Please note that these alternative products are Z-rated. Therefore, these are not FDA-approved drugs and are not listed as therapeutically interchangeable with brand-name Chantix.)

Information for providers:1

    We have sent a letter to your Humana-covered patients who have had a claim for Chantix and asked them to contact their physicians or healthcare providers if their medication is included in the recall and if they have experienced problems that may be related to using these drug products. 

    Healthcare providers with questions can contact:            Pfizer Medical Information at 800-438-1985, option 3, Monday – Friday, 9 a.m. – 5 p.m., Eastern time; or refer to www.pfizermedinfo.com for medical questions regarding the product.

        Pfizer Drug Safety at 800-438-1985, option 1 (24 hours a day, 7 days a week) to report adverse events and product complaints.



    Patients may report adverse reactions or quality problems experienced with the use of this product to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.            Online: Complete and submit the        report.

                    Select “Consumer/Patient (FDA Form 3500B).”

                Regular mail or fax: Download the        form                    Select “Form FDA 3500B – Voluntary Reporting for Consumers” and submit by mail to the address on the form or by fax to 800-FDA-0178 (332-0178).





*For Florida Medicaid, please note that these alternatives are not included on the Agency for Health Care Administration’s Preferred Drug List.

    “Pfizer Expands Voluntary Nationwide Recall to include All Lots of CHANTIX® (Varenicline) Tablets Due to N-Nitroso Varenicline Content,” U.S. Food and Drug Administration, last accessed November 29, 2021,    www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/pfizer-expands-voluntary-nationwide-recall-include-all-lots-chantixr-varenicline-tablets-due-n?utm_medium=email&utm_source=govdelivery.



Drug recall notice for Nature-Throid and WP Thyroid tablets

Drug recall notice for Belviq, Belviq XR (lorcaserin)

Drug recall notice for NP Thyroid tablets

Drug recall notice for Taro Pharmaceuticals phenytoin oral suspension

Formulary changes for generic Ventolin HFA

Impact of ongoing angiotensin II receptor blocker drug recalls

Referencia:

Noticias sobre farmacia

Alternativas preferidas
Apo-Vareniclina 0.5 mg, comprimidos
Apo-Vareniclina 1 mg, comprimidos
Apo-Vareniclina 0.5 mg y 1 mg paquete inicial de comprimidos

Referencia:​​

Noticias sobre farmacia​​

Referencia:

Noticias sobre farmacia